Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MARS1 | P56192 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13906326 | 0.87 | HSD11B1 (0.47) | AHRHSD11B1SRD5A2DPP4TP53 | |
| SCHEMBL19323001 | 0.86 | HPGD (0.45) | AHRTP53 | |
| SCHEMBL2933108 | 0.86 | AHR (0.67) | AHRHSD11B1SRD5A2MARS1TP53 | |
| SCHEMBL13494486 | 0.83 | NOTUM (0.44) | HSD11B1DPP4HSP90AB1 | |
| SCHEMBL1047205 | 0.83 | TP53 (0.42) | AHRHSD11B1DPP4HSP90AB1TP53 | |
| SCHEMBL27395925 | 0.81 | NOTUM (0.43) | HSD11B1DPP4HSP90AB1 | |
| SCHEMBL14202693 | 0.79 | CYP3A4 (0.52) | DPP4POLBTP53 | |
| SCHEMBL12508331 | 0.79 | GRM2 (0.44) | HSD11B1 | |
| SCHEMBL26572467 | 0.79 | HSD11B1 (0.46) | HSD11B1TP53 | |
| SCHEMBL9254409 | 0.79 | AHR (0.59) | AHRHSD11B1SRD5A2MARS1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3153501-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2799428-B1 | Glucagon antagonists | METABASIS THERAPEUTICS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0126369-B2 | PROCESS FOR THE PREPARATION OF HIGH-MOLECULAR POLYARYLENE SULFIDES WHICH MAY BE BRANCHED | BAYER AG (DE) | 1991-12-18 | — | — | EP | disclosed |
| EP-0126369-B1 | PROCESS FOR THE PREPARATION OF HIGH-MOLECULAR POLYARYLENE SULFIDES WHICH MAY BE BRANCHED | BAYER AG (DE) | 1988-08-10 | — | — | EP | disclosed |
| US-4663430-A | Process for the preparation of high molecular weight polyarylene sulphide in the absence of water | BAYER AKTIENGESELLSCHAFT (DE) | 1987-05-05 | — | — | US | disclosed |
| EP-0126369-A1 | Process for the preparation of high-molecular polyarylene sulfides which may be branched | BAYER AG (DE) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AHR 1203/4885HSD11B1 312/4885SRD5A2 1508/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | AHR 1471/4885HSD11B1 256/4885SRD5A2 167/4885 |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | CIT, PTGIS, PTGIR | AHR 3102/4885HSD11B1 707/4885SRD5A2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.